Charles River Acquires Retrogenix
We are pleased to announce that Charles River has completed the acquisition of Retrogenix, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances Charles River’s scientific expertise with additional large molecule and cell therapy discovery capabilities.
Retrogenix offers cell microarray services for target receptor identification, off-target profiling, and target deconvolution on a wide range of novel therapeutics including biologics, cell therapies, and small molecules, and provides the premier platform for off-target screening for preclinical safety assurance in CAR-T therapies. Combined with Distributed Bio’s large-molecule discovery platform, the acquisition of Retrogenix will further strengthen Charles River’s integrated, end-to-end solution for therapeutic antibody and cell and gene therapy discovery and development.